FDA clears AbbVie’s Decnupaz for ultra-rare blood cancer: full analysis

CURRENT FULL VERSION: AbbVie has picked up a new US FDA oncology approval, with Decnupaz (pivekimab sunirine-pvzy) cleared on May 27, 2026, for adults with blastic plasmacytoid dendritic cell neoplasm, or BPDCN. The drug is a CD123-directed antibody and alkylating agent conjugate, and the approval gives patients with an ultra-rare blood cancer another treatment option in a disease long defined by limited choices and poor outcomes. (fda.gov)

The background matters here. BPDCN is rare, aggressive, and often presents first with skin lesions before spreading to bone marrow, lymph nodes, and the central nervous system. The disease tends to affect older adults, and relapse after intensive treatment has remained a major problem. Until recently, the treatment landscape was exceptionally thin: tagraxofusp-erzs became the first FDA-approved BPDCN therapy in December 2018. Decnupaz now enters that space as a newer targeted option built around the same CD123 biology, but with a different drug design. (prnewswire.com)

The FDA based its decision on the multicenter, open-label, single-arm CADENZA trial, identified as NCT03386513. That global Phase 1/2 study enrolled 84 adults with CD123-positive hematologic malignancies, including the BPDCN cohorts used for the approval, and excluded patients with active CNS disease. The registrational BPDCN population included 33 patients with treatment-naive disease and 51 with relapsed or refractory disease. The primary efficacy measure was complete remission or clinical complete remission. According to the FDA, 23 of 33 treatment-naive patients, or 69.7%, reached that endpoint after a median follow-up of 21.5 months, with a median remission duration of 9.7 months. In the relapsed or refractory group, 8 of 51 patients, or 15.7%, achieved remission after a median follow-up of 24.1 months, with a median remission duration of 9.2 months. (fda.gov)

Additional trial reporting helps fill in the picture. Data presented in 2025 and later published in the Journal of Clinical Oncology described pivekimab sunirine as a first-in-class CD123 antibody-drug conjugate using an indolinobenzodiazepine pseudodimer payload. In the frontline de novo subgroup, response rates appeared even stronger, and roughly half of first-line responders were bridged to stem cell transplant in the conference dataset, suggesting the drug may have utility as a path to transplant for some patients. Separate reporting on the approval said 13 newly diagnosed patients subsequently underwent stem cell transplant, while 6 patients in the relapsed or refractory group were able to receive post-study transplant. That said, the evidence package remains from a single-arm study in a very small population, which is typical in ultra-rare cancers but still limits cross-trial comparisons. (epostersonline-2.s3.amazonaws.com)

Safety will be central to how the approval is received in practice. The FDA-approved prescribing information includes a boxed warning for hepatotoxicity, including hepatic veno-occlusive disease, along with warnings for infusion-related reactions, edema, sulfite allergic reactions, and embryo-fetal toxicity. AbbVie said the most common adverse reactions, each seen in at least 20% of patients, were edema, fatigue, musculoskeletal pain, hemorrhage, infusion-related reactions, nausea, and diarrhea. The FDA also granted the application priority review, and the drug had previously received breakthrough therapy and orphan drug designations. (fda.gov)

Industry coverage has framed the decision as AbbVie’s first approved antibody-drug conjugate in this niche indication and a notable milestone in rare hematologic malignancies. BioSpace highlighted both the high frontline remission rate and the liver safety signal, underscoring the same tension likely to shape clinician adoption: strong activity in a disease with few options, but meaningful toxicity that will require careful patient selection and monitoring. AbbVie, for its part, positioned the approval as part of its broader oncology strategy and said it is also studying the asset in acute myeloid leukemia. (biospace.com)

Why it matters: For veterinary professionals, this is another reminder that oncology innovation in human medicine continues to move toward highly targeted conjugates aimed at narrow biomarkers and rare populations. Even though BPDCN itself is a human disease, the approval is relevant as a signal of where translational oncology is heading: more biomarker-defined therapies, more use of single-arm registrational studies in rare cancers, and more emphasis on managing serious adverse events as targeted drugs move into practice. The transplant-bridging signal in CADENZA adds another practical point of interest, showing how targeted agents in hematologic malignancies may be used not only for disease control but also to move selected patients toward definitive procedures. For teams following comparative oncology, drug development strategy, or the oncology investment landscape, Decnupaz is a useful case study in how companies are building value in very small indications first, then looking for expansion into broader hematologic cancers. (fda.gov)

What to watch: The next questions are how quickly Decnupaz is adopted against existing BPDCN treatment patterns, whether post-approval safety experience changes comfort around hepatotoxicity and transplant sequencing, and whether AbbVie can convert the platform into follow-on indications such as acute myeloid leukemia. (fda.gov)